Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: modernatx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/19/2024 | $42.00 | Hold | Berenberg |
| 11/18/2024 | $58.00 | Hold → Buy | HSBC Securities |
| 11/15/2024 | $40.00 | Underperform | Wolfe Research |
| 10/17/2024 | $55.00 | Mkt Perform | Bernstein |
| 9/13/2024 | $120.00 → $65.00 | Buy → Hold | Jefferies |
| 9/13/2024 | $88.00 → $70.00 | Neutral → Underweight | JP Morgan |
| 9/13/2024 | Outperform → Perform | Oppenheimer | |
| 8/28/2024 | $82.00 | Reduce → Hold | HSBC Securities |
| 8/7/2024 | $85.00 → $80.00 | Sell → Hold | Deutsche Bank |
| 8/5/2024 | $125.00 → $90.00 | Outperform → Sector Perform | RBC Capital Mkts |
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
3 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
4 - Moderna, Inc. (0001682852) (Issuer)
Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billionInitiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenzaAnnounces expansion of its Executive Committee CAMBRIDGE, MA / ACCESSWIRE / November 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2024."During the third quarter, we focused on execution with the launch of our updated COVID-19 and RSV vaccines in markets across the globe. I
CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the adv
Reports second quarter revenues of $241 million, GAAP net loss of $1.3 billion and GAAP EPS of $(3.33)Updates 2024 financial framework and revises expectations for product sales to $3.0 to $3.5 billionReceived U.S. FDA approval for RSV vaccine, mRESVIA, and began shipping in July; received EMA positive opinion in JuneAnnounced positive Phase 3 data for combination vaccine against influenza and COVID-19Announced positive Phase 3 data for next-generation COVID-19 vaccine CAMBRIDGE, MA / ACCESSWIRE / August 1, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2024."During the second quarter, we marked the approval of our
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advance
Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billionInitiated three new clinical studies evaluating Moderna's investigational individualized neoantigen therapy in combination with Merck's Keytruda® for treatment of patients with bladder cancer, kidney cancer and cutaneous squamous cell carcinomaAdvanced three new vaccine programs (Epstein-Barr virus, Varicella-Zoster virus, norovirus) toward Phase 3 clinical trials as announced at Vaccines Day investor eventCAMBRIDGE, MA / ACCESSWIRE / May 2, 2024 / Mod
CAMBRIDGE, MA / ACCESSWIRE / April 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024 to report its first quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the advancemen
Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55Reports full-year revenues of $6.8 billion, GAAP net loss of $(4.7) billion and GAAP diluted EPS of $(12.33); loss primarily driven by mostly non-cash charges of $3.7 billion related to resizing and a tax valuation allowanceReaffirms 2024 expected product sales of approximately $4 billionExpects regulatory approvals for its investigational RSV vaccine for older adults beginning in first half of 2024, and anticipates additional key milestones from its late-stage pipeline this yearCAMBRIDGE, MA / ACCESSWIRE / February 22, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial result
CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine.
Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billionSpikevax U.S. market share to date increased to 45% from 36% in 2022Company anticipates 2024 revenue of approximately $4 billion and return to growth in 2025Company has significantly improved future cost of sales by resizing its manufacturing capacity, contributing to a third quarter net loss of $3.6 billion, primarily driven by mostly non-cash charges of $3.1 billion related to resizing and a tax valuation allowanceCompany's late-stage pipeline has six Phase 3 programsCompany expects to break even in 2026 through product launches and disciplined investmentCAMBRIDGE, MA / ACCESSWIRE / November 2,
CAMBRIDGE, MA / ACCESSWIRE / October 12, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023 to report its third quarter 2023 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaIn over 10 years since its inception, Moderna has transformed from a research-stage
Berenberg initiated coverage of Moderna with a rating of Hold and set a new price target of $42.00
HSBC Securities upgraded Moderna from Hold to Buy and set a new price target of $58.00
Wolfe Research initiated coverage of Moderna with a rating of Underperform and set a new price target of $40.00
Bernstein initiated coverage of Moderna with a rating of Mkt Perform and set a new price target of $55.00
Jefferies downgraded Moderna from Buy to Hold and set a new price target of $65.00 from $120.00 previously
JP Morgan downgraded Moderna from Neutral to Underweight and set a new price target of $70.00 from $88.00 previously
Oppenheimer downgraded Moderna from Outperform to Perform
HSBC Securities upgraded Moderna from Reduce to Hold and set a new price target of $82.00
Deutsche Bank upgraded Moderna from Sell to Hold and set a new price target of $80.00 from $85.00 previously
RBC Capital Mkts downgraded Moderna from Outperform to Sector Perform and set a new price target of $90.00 from $125.00 previously
10-Q - Moderna, Inc. (0001682852) (Filer)
8-K - Moderna, Inc. (0001682852) (Filer)
8-K - Moderna, Inc. (0001682852) (Filer)
8-K - Moderna, Inc. (0001682852) (Filer)
10-Q - Moderna, Inc. (0001682852) (Filer)
8-K - Moderna, Inc. (0001682852) (Filer)
144 - Moderna, Inc. (0001682852) (Subject)
144 - Moderna, Inc. (0001682852) (Subject)
8-K - Moderna, Inc. (0001682852) (Filer)
144 - Moderna, Inc. (0001682852) (Subject)
For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 42.19% on an annualized basis producing an average annual return of 54.8%. Currently, Moderna has a market capitalization of $45.66 billion. Buying $1000 In MRNA: If an investor had bought $1000 of MRNA stock 5 years ago, it would be worth $8,701.97 today based on a price of $119.13 for MRNA at the time of writing. Moderna's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and revie
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume BSX PUT SWEEP BEARISH 08/16/24 $75.00 $68.9K 5.5K 2.1K MRNA CALL SWEEP NEUTRAL 11/15/24 $170.00 $121.
Directors Robert Langer and Stephen Berenson will also retire from the Board.
Investors with a lot of money to spend have taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen. So how do we know what these investors just did? Today, Benzinga's options scanner spotted 8 uncommon options trades for Moderna. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 37%, bearish. Out of all of the special opt
Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 75% with bearish. From the overall spotted trades, 6 are puts, for a total amount of $218,807 and 2, calls, for a total amount of $70,833. Expected Price Movements Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $110.0 to $150.0 for Moderna over the recent three months. Volume & Open Interest Trends Examining the volume and
More than half of the states in the U.S. are experiencing significant Covid-19 activity in wastewater, and President Joe Biden remains in isolation after announcing Wednesday he caught the virus for the third time. Twenty-six states are reporting either “high” or “very high” levels of the virus at various sites, according to the latest data from the Centers for Disease Control and Prevention. States with the highest levels include Arkansas, California, Florida, Maryland, Nevada, Oregon and Texas. The Biden administration no longer considers Covid-19 a public health emergency and instead treats it as a routine respiratory virus to be prevented through an annual vaccination campaign,
The European Commission faced criticism from Europe’s second-highest court regarding transparency issues surrounding COVID-19 vaccine contracts from four years ago. This scrutiny comes on the eve of a crucial vote on Commission head Ursula von der Leyen‘s reelection bid. Some European lawmakers have been vocal about their dissatisfaction with how the Commission handled its multibillion-euro contracts, particularly its failure to disclose text messages between von der Leyen and Pfizer Inc (NYSE:PFE) CEO Albert Bourla regarding one of the agreements. In 2022, a Pfizer executive “categorically” ruled out that the pharma giant’s chief executive agreed on the European COVID-19 contract v
The Nasdaq 100 closed higher by more than 100 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga’s insider transactions platform. DICK’S Sporting Goods The Trade: DICK’S Sporting Goods, Inc. (NYSE:DKS) Director Desiree Ralls-Morrison sold a total of 3
Avian influenza, also known as bird flu, has public health officials on alert after it spread to an unprecedented number of cows in the U.S. this year and led to positive tests of the virus in four U.S. dairy workers so far this year. A severe variant of the H5N1 strain infected animals ranging from alpacas to house cats worldwide since 2020 and caused lethal outbreaks in commercial poultry, but this is the first year it has infected cows, Reuters reported. Humans have contracted different bird flu strains in Australia and Mexico, while different H5 subtypes have also shown up in other parts of the world including China and Cambodia. Most of the human cases have come from exposure t
In a recent development, Flagship Pioneering, the venture capital firm known for backing Moderna (NASDAQ:MRNA) has successfully secured a whopping $3.6 billion in funding. What Happened: Flagship Pioneering has raised $2.6 billion for its eighth fund and an additional $1 billion for parallel funds. These parallel funds will be invested in specific sectors such as diagnostics or therapeutics. The venture firm is also planning to raise more funds for its eighth fund later this year. The funds are intended to launch a series of new biotech companies that will harness the power of generative artificial intelligence for drug discovery, The Financial Times reported on Wednesday. Noubar Afeya
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
SC 13G/A - Moderna, Inc. (0001682852) (Subject)
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
Ampersand's AND™ Platform will be used to identify programmed biologics for the treatment of obesity-related targets Montai's CONECTA™ AI platform will be used to identify small molecules directed to a potential Non-Small Cell Lung Cancer-related target Collaborations will leverage Pfizer's deep expertise in early discovery and development for cardiometabolic and cancer treatments, two priority therapeutic areas for the company CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further dev
Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.
Valo Elevates Brett Blackman to Chief Operating Officer and Appoints Travis Wilson to its Board of Directors CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Valo Health today announced that industry leader Brian M. Alexander, M.D., M.P.H. has been appointed Chief Executive Officer of Valo Health and CEO-Partner of Flagship Pioneering. Dr. Alexander brings two decades of biotechnology, biopharma, and medical leadership, most recently as SVP, Research & Development and Head of Boston Roche Innovation Center (BRIC), for Roche/Genentech and previously as CEO of Foundation Medicine. Valo also announced the appointments of Brett Blackman
CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation."We are honored to be recognized by BioSpace as the most desirable large employer in the life sciences industry for the fourth year in a row," said Stéphane Bancel, Chief Executive Officer of Moderna. "I am proud of the company we are building and the investments we have made in our team. We remain focused on creating an environment where employees can have meaningful careers, and where curiosity, purpose and innovation drive our mission for patients
mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringesCanada is the fourth jurisdiction to approve mRESVIA following approvals in the U.S., Europe, and QatarCAMBRIDGE, MA / ACCESSWIRE / November 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced Health Canada has approved mRESVIA™ (Respiratory Syncytial Virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.1"Today's approval is an example of how our mRNA platform can help address significant public health challenges like RSV," sa
New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADELPHIA, Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (NASDAQ:MRNA). The data demonstrated that the development candidate can successfully create CAR-M directly
Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billionInitiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenzaAnnounces expansion of its Executive Committee CAMBRIDGE, MA / ACCESSWIRE / November 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2024."During the third quarter, we focused on execution with the launch of our updated COVID-19 and RSV vaccines in markets across the globe. I
Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors PHILADELPHIA, Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for the treatment of hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (NASDAQ:MRNA). The data will be presented in a poster session at the Society for Immunother
CAMBRIDGE, MA / ACCESSWIRE / October 31, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences:Guggenheim's Inaugural Healthcare Innovation Conference, on Tuesday, November 12th at 10:00am ETUBS Global Healthcare Conference, on Wednesday, November 13th at 3:30pm PTJefferies London Healthcare Conference, on Thursday, November 21st at 2:00pm GTA live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.About Mod
CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin
Williams was promoted from Operating Partner at Flagship Pioneering and President at Apriori Bio Apriori Bio has made significant progress in 2024, including securing a collaboration with CEPI, assembling a world class board of directors and building out an early pipeline of prospective vaccines CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Apriori Bio, a biotechnology company aimed at providing humanity with variant-resilient protection against rapidly-evolving viruses, today announced that Craig Williams, MBA, has been promoted to CEO-Partner at Flagship Pioneering and Chief Executive Officer of Apriori.
Valo Elevates Brett Blackman to Chief Operating Officer and Appoints Travis Wilson to its Board of Directors CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Valo Health today announced that industry leader Brian M. Alexander, M.D., M.P.H. has been appointed Chief Executive Officer of Valo Health and CEO-Partner of Flagship Pioneering. Dr. Alexander brings two decades of biotechnology, biopharma, and medical leadership, most recently as SVP, Research & Development and Head of Boston Roche Innovation Center (BRIC), for Roche/Genentech and previously as CEO of Foundation Medicine. Valo also announced the appointments of Brett Blackman
CAMBRIDGE, Masss. and LONDON, Oct. 23, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that Junaid Bajwa, M.D., has joined its London office as Senior Partner and Head of United Kingdom. In this role, Dr. Bajwa will play an integral role in advancing new strategic opportunities and partnerships for Flagship and its ecosystem of companies in the United Kingdom and throughout Europe. Dr. Bajwa will also serve as Science Partner for Pioneering Intelligence, Flagship's strategic initiative that is building unique AI/ML knowledge to accelerate innovation across the ecosystem.
CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that Paul Parker has joined as Managing Partner, Capital Solutions and Value Realization. In this role, Parker will lead all capital solutions efforts at Flagship, driving portfolio value realization, fundraising activities, and building and managing Flagship's relationships with Limited Partners as well as strategic and financial investors. He will also play a key role on Flagship's senior leadership team, helping drive value, impact, and effectiveness across the organization.
CAMBRIDGE, Mass., Oct. 3, 2024 /PRNewswire/ -- Invaio Sciences, a Flagship Pioneering bioplatform company focused on accelerating the leap to nature-positive agriculture, today announced the appointment of André Andonian as the new Chairman of its Board of Directors. Robert Berendes has decided to step down after serving as Chairman of the Board since 2019 and will continue to serve on the board of Invaio. Andonian is Chair of Asia Pacific and Strategic Advisor at Flagship Pioneering, where he and Ignacio Martinez are responsible partners for Invaio. He is also Senior Partner
Hussain brings more than 35 years of commercial leadership and operating experience in healthcare, most recently serving as CEO of Vifor PharmaAs former Global President of GSK, Pharmaceuticals and Vaccines, Hussain brings significant global vaccine commercialization experience in emerging and mature markets, along with significant Board of Directors expertise CAMBRIDGE, MA / ACCESSWIRE / October 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that Abbas Hussain, former Chief Executive Officer of Vifor Pharma, has joined Moderna's Board of Directors, effective October 2, 2024."As Moderna accelerates our global commercialization efforts, Abbas is a tremendous addition to our Board," sai
Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that globally distinguished healthcare expert, entrepreneur, and public policy leader Raj Panjabi, M.D., MPH, will join Flagship as Senior Partner. Dr. Panjabi will lead Flagship's Preemptive Health and Medicine Initiative (PH&M), which is pioneering a new field to protect, maintain, or improve people's health before they get sick. In its fifth year, the initiative is grounded in the premise that health should be accessible for all and pursues interventions that prot
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
O'Shea is a Seasoned Global Executive with more than 20 Years' Experience across the Agriculture, Food and Pharmaceutical Industries CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director. O'Shea is a seasoned global executive with more than 20 years' experience across the agriculture, food, and phar